For the nine months ended September 30, 2026, Stoke Therapeutics reported a net loss of $185.3 million, a significant reversal from a net income of $51.0 million in the prior year period, primarily due to a sharp decrease in revenue from $183.0 million to $26.8 million. Operating expenses rose substantially, with research and development costs increasing by 55% to $149.0 million as the company advances its clinical programs for zorevunersen.
Stoke Therapeutics reported Q3 2026 financial results, highlighting a cash position of $358.8 million which is expected to fund operations into early 2028. The company provided clinical updates on its Phase 3 EMPEROR study for Dravet syndrome, with a data readout anticipated in Q3 2027 and a planned NDA submission in H2 2027.
Term
Q3 2026
“The Phase 3 EMPEROR study of zorevunersen continues to progress well. Approximately 110 of 162 enrolled patients have completed their Week 28 visit when the primary endpoint of change in major motor seizure frequency is measured and approximately 20 are through Week 52, the end of the treatment period. All 20 of these patients are continuing into the open-label extension period of the study and to date, no patients have discontinued treatment.”
Ian F. Smith, Chief Executive Officer and Director of Stoke Therapeutics
“Our second clinical program, STK-002, targets the protein haploinsufficiency that causes ADOA and therefore may have the potential to improve vision in people living with this severe genetic disease that often leads to blindness. Dosing in the first two cohorts is complete and dosing in the third cohort is underway with the fourth cohort expected to follow in early 2027.”
Ian F. Smith, Chief Executive Officer and Director of Stoke Therapeutics